Moderna (NASDAQ:MRNA) Trading Down 4.7% - Should You Sell?

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) shares dropped 4.7% on Monday . The company traded as low as $37.08 and last traded at $37.56. Approximately 2,802,809 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 12,083,261 shares. The stock had previously closed at $39.42.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research reports. UBS Group cut their price target on shares of Moderna from $108.00 to $96.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Bank of America reiterated an "underperform" rating and issued a $41.00 price objective on shares of Moderna in a report on Tuesday, December 10th. Evercore ISI lowered their target price on shares of Moderna from $60.00 to $50.00 and set an "in-line" rating on the stock in a report on Monday, January 27th. Leerink Partners decreased their price objective on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Moderna from $59.00 to $45.00 and set an "underweight" rating on the stock in a report on Tuesday, November 26th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $67.26.

Moderna Price Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm has a market cap of $13.46 billion, a P/E ratio of -6.01 and a beta of 1.59. The company's 50-day moving average is $40.59 and its two-hundred day moving average is $59.22.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business's quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. Sell-side analysts anticipate that Moderna, Inc. will post -9.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company's stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 2,664 shares of company stock valued at $115,210. 15.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MRNA. Axiom Advisory LLC increased its position in Moderna by 1.6% during the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company's stock valued at $847,000 after purchasing an additional 198 shares during the period. Arkadios Wealth Advisors increased its position in Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company's stock valued at $764,000 after purchasing an additional 243 shares during the period. Knuff & Co LLC increased its position in Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock valued at $316,000 after purchasing an additional 244 shares during the period. Stephens Inc. AR increased its position in Moderna by 7.9% during the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company's stock valued at $223,000 after purchasing an additional 245 shares during the period. Finally, Mather Group LLC. increased its position in Moderna by 25.7% during the 3rd quarter. Mather Group LLC. now owns 1,281 shares of the company's stock valued at $86,000 after purchasing an additional 262 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.